$GMAB

Morgan Stanley initiated coverage on Genmab (GMAB) with an Equalweight rating and a $42 price target. The stock trades at $38.50 with a $22.81B market cap. Darzalex contributed 65% of 2025 revenue, with royalties ending in 2029-2031. Morgan Stanley models revenue peaking at $8.63B in 2030 before declining. Genmab reported Q2 2026 earnings of $4.91 per share, exceeding estimates, and raised 2026 revenue guidance to DKK 4.3B-4.5B. Other analysts raised price targets to $50 and $54.

Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% compared to R-CHOP alone in the Phase 3 EPCORE DLBCL-2 trial. The company plans to present these results and share them with regulators. Additionally, Genmab announced Q3 2026 net sales of $4.239B for DARZALEX, generating royalties for the company.

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

Genmab reported Q3 2026 DARZALEX net sales of $4.24B, with $2.53B in the U.S. and $1.71B rest of world, according to J&J. Genmab earns royalties on these sales, which are a key revenue driver.

Genmab (GMAB) rose to a 3-year high after positive Phase 3 trial results for Epkinly with AbbVie, showing reduced risk in lymphoma patients. Analysts reiterated Buy ratings, forecasting multi-billion USD sales. Shareholders approved a pay plan, and the company granted 5,300 RSUs to executives.

Analysts from Truist Financial and Bank of America maintained Buy ratings on Genmab (GMAB), with price targets of $45.00 and DKK2,850.00, respectively. Genmab reported Q2 revenue of $1.16B and net profit of $303M, up from $924.81M and $335.93M in the same period last year.

Deutsche Bank increased its price target for Genmab to DKK 3,000 from DKK 2,750 and maintained a buy rating. Barclays also raised its target to DKK 3,100 from DKK 2,900, keeping an overweight rating. Genmab's stock is currently trading at 2,356.00 DKK on Nasdaq Copenhagen.

Genmab A/S (Nasdaq: GMAB) approved a proposal to grant 5,300 restricted stock units to its board members at an extraordinary general meeting. Each unit, valued at DKK 2,487.00, vests after three years and is tied to the company's share price. The move aligns with Genmab's remuneration policy.

Genmab (CPSE:GMAB) and AbbVie reported positive Phase 3 trial results for epcoritamab plus R-CHOP in lymphoma patients, showing a 51% reduction in disease progression risk. The trial's success may impact Genmab's long-term treatment positioning and regulatory discussions. Genmab's investment narrative depends on trial success and partner deals, with recent earnings showing reduced profit margins and debt concerns.

NeOnc Technologies Holdings reported encouraging survival data for its NEO100 treatment in a Phase 2a study of recurrent brain cancer, with a median overall survival of 26.09 months. Revolution Medicines' Rasonque received FDA approval for pancreatic cancer, showing a median overall survival of 13.2 months.